Gilead Trodelvy First-Line TNBC Approval
The FDA approved Trodelvy for first-line metastatic triple-negative breast cancer, significantly expanding Gilead’s commercial opportunity and reinforcing TROP2-directed ADCs as a leading oncology modality.
Triple-Negative Breast Cancer
